{"id":"NCT01068678","sponsor":"Novo Nordisk A/S","briefTitle":"Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes","officialTitle":"A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGINâ„¢: EASY AM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2010-02-15","resultsPosted":"2015-12-28","lastUpdate":"2017-03-06"},"enrollment":460,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]}],"arms":[{"label":"IDeg 3 times weekly (3TW)","type":"EXPERIMENTAL"},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Africa, Asia, Europe, and North America. The aim of this clinical trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes currently treated with metformin alone or with metformin combined with an oral anti-diabetic drug (OAD) qualifying for intensified treatment.","primaryOutcome":{"measure":"Change in Glycosylated Haemoglobin (HbA1c)","timeFrame":"Week 26","effectByArm":[{"arm":"IDeg 3TW","deltaMin":-1,"sd":0.95},{"arm":"IGlar OD","deltaMin":-1.4,"sd":1.07}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":99,"countries":["United States","Canada","Czechia","Israel","Puerto Rico","Slovakia","South Africa","United Kingdom"]},"refs":{"pmids":["24622318"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":227},"commonTop":["Headache","Diarrhoea","Nasopharyngitis","Back pain","Nausea"]}}